|Mission type||Technology demonstration|
|Mission duration||Failed to orbit|
60 days (planned)
|Manufacturer||NASA Ames Research Center|
|Launch mass||4.5 kg (9.9 lb)|
|Power||Solar cells and batteries|
|Start of mission|
|Launch date||3 August 2008, 03:34 UTC|
|Rocket||Falcon 1 # 3|
|Launch site||Kwajalein Atoll, Omelek|
|Reference system||Geocentric orbit (planned) |
|Regime||Low Earth orbit|
|Perigee altitude||330.0 km (205.1 mi)|
|Apogee altitude||685.0 km (425.6 mi)|
PharmaSat Risk Evaluation Satellite (or PRESat) nanosatellite, for NASA, was about the size of a loaf of bread, weighed about 4.5 kg (9.9 lb) and was constructed in just six months.
PRESat, 3U CubeSat, contains a micro-laboratory with a controlled environment packed with sensors and optical systems that can detect the growth, density and health of yeast cells. PRESat was to demonstrate its ability to create a stable, space science laboratory using innovative environment control techniques, and to monitor the levels of pressure, temperature and acceleration.
The satellite was lost in the failure of the third Falcon 1 launch, on 3 August 2008, at 03:34 UTC.
Although NASA was not able to test this payload in space, NASA mission managers and payload engineers achieved success in this low-cost mission by rapidly pulling together expertise from across the agency to develop, build and ground-test a fundamental space biology micro-laboratory. The communications team also successfully established a fully operational South Pacific Ground Communication System using two ground stations, which were transported and installed at Kwajalein Atoll in the Marshall Islands and at the Universidad Centroamericana in El Salvador.
This mission was to provides an excellent opportunity for collaboration between two NASA centers, other government agencies, academia and the burgeoning space industry. Through the development of PRESat, NASA gained experience and knowledge it can apply to future small and nanosatellite missions.